Minimal clinically important difference (MCID) can be defined as the smallest change or difference in an outcome measure that is perceived as beneficial and would lead to a change in the patient’s medical management. The aim of the current expert consensus report is to provide a “state-of-the-art” review of the currently available literature evidence about MCID for end-points to monitor asthma control, in order to facilitate optimal disease management and identify unmet needs in the field to guide future research. A series of MCID cut-offs are currently available in literature and validated among populations of asthmatic patients, with most of the evidence focusing on outcomes as patient reported outcomes, lung function and exercise tolerance. On the contrary, only scant and partial data are available for inflammatory biomarkers. These clearly represent the most interesting target for future development in diagnosis and clinical management of asthma, particularly in view of the several biologic drugs in the pipeline, for which regulatory agencies will soon require personalised proof of efficacy and treatment response predictors.

Minimal clinically important difference for asthma endpoints. An expert consensus report / Bonini, M.; Di Paolo, M.; Bagnasco, D.; Baiardini, I.; Braido, F.; Caminati, M.; Carpagnano, E.; Contoli, M.; Corsico, A.; Giacco, S. D.; Heffler, E.; Lombardi, C.; Menichini, I.; Milanese, M.; Scichilone, N.; Senna, G.; Canonica, G. W.. - In: EUROPEAN RESPIRATORY REVIEW. - ISSN 0905-9180. - 29:156(2020), pp. 1-14. [10.1183/16000617.0137-2019]

Minimal clinically important difference for asthma endpoints. An expert consensus report

Bonini M.
Primo
;
Di Paolo M.
Secondo
;
Menichini I.;
2020

Abstract

Minimal clinically important difference (MCID) can be defined as the smallest change or difference in an outcome measure that is perceived as beneficial and would lead to a change in the patient’s medical management. The aim of the current expert consensus report is to provide a “state-of-the-art” review of the currently available literature evidence about MCID for end-points to monitor asthma control, in order to facilitate optimal disease management and identify unmet needs in the field to guide future research. A series of MCID cut-offs are currently available in literature and validated among populations of asthmatic patients, with most of the evidence focusing on outcomes as patient reported outcomes, lung function and exercise tolerance. On the contrary, only scant and partial data are available for inflammatory biomarkers. These clearly represent the most interesting target for future development in diagnosis and clinical management of asthma, particularly in view of the several biologic drugs in the pipeline, for which regulatory agencies will soon require personalised proof of efficacy and treatment response predictors.
2020
minimal clinically important difference; asthma; lung function; biomarkers
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Minimal clinically important difference for asthma endpoints. An expert consensus report / Bonini, M.; Di Paolo, M.; Bagnasco, D.; Baiardini, I.; Braido, F.; Caminati, M.; Carpagnano, E.; Contoli, M.; Corsico, A.; Giacco, S. D.; Heffler, E.; Lombardi, C.; Menichini, I.; Milanese, M.; Scichilone, N.; Senna, G.; Canonica, G. W.. - In: EUROPEAN RESPIRATORY REVIEW. - ISSN 0905-9180. - 29:156(2020), pp. 1-14. [10.1183/16000617.0137-2019]
File allegati a questo prodotto
File Dimensione Formato  
Bonini_Minimal_2020.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 471.33 kB
Formato Adobe PDF
471.33 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1495773
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 76
  • ???jsp.display-item.citation.isi??? 63
social impact